Back to News
Market Impact: 0.25
Teva To Discontinue TOPAS-MSA Study In Adults With Multiple System Atrophy
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, will discontinue the Phase 2 TOPAS-MSA study of emrusolmin (TEV-286) in adults with multiple system atrophy. The article excerpt says the decision followed a recommendation but cuts off before identifying its source; no financial or market impact figures are provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment
TEVA-0.70
More News
- Neurocrine earnings in focus as Ingrezza pricing pressure looms
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash